Duke Health researchers have identified a unique process within the environment of glioblastoma brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
A large study by researchers at the American Cancer Society demonstrated that adult cancer survivors, particularly those diagnosed within five years and/or those who have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to older adults without cancer.
Research findings from the Johns Hopkins Kimmel Cancer Center show how higher viscosity, or resistance to flow, of the extracellular fluid that surrounds cells enables cancer cells to migrate more rapidly from a primary tumor to other sites in the body.
Researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.
Researchers at VCU Massey Cancer Center published study findings that establish rationale for the use of a class of drugs known as MDA-9 inhibitors as a potential treatment option for aggressive liver cancer.
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco has discovered the underlying cause of gender differences in treatment-associated myocarditis after immune checkpoint inhibitor treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.
FDA issued a revised draft guidance for industry, “Expanded Access to Investigational Drugs for Treatment Use Questions and Answers.”
Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products.
Carrum Health and AccessHope LLC formed a collaboration to bring cancer expertise to people living with cancer.
The National Cancer Institute approved the following clinical research studies last month.
